ILF2 overexpression, driven by 1q21 copy number alterations, promotes adaptive responses to DNA damage in a dose-dependent manner, which explains why MM patients with the 1q21 gain/amplification benefit less from high-dose chemotherapy than patients without the gain/amplification. Here, ILF2 is linked to Miyoshi myopathy.